| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Galera Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 11K | $24.7K | $2.25 | Mar 16, 2023 | Direct |
| Galera Therapeutics, Inc. | Chief Commercial Officer | Stock Option (Right to Buy) | 135K | Feb 25, 2023 | Direct | ||
| Lyell Immunopharma, Inc. | Director | Option (right to buy) | 13K | Jun 9, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| LYEL | Lyell Immunopharma, Inc. | Jun 9, 2025 | 1 | $0 | 4 | Jun 11, 2025 | Director |
| LYEL | Lyell Immunopharma, Inc. | Jun 9, 2025 | 0 | $0 | 3 | Jun 11, 2025 | Director |
| GRTX | Galera Therapeutics, Inc. | Mar 16, 2023 | 1 | $24.7K | 4 | Mar 20, 2023 | Chief Commercial Officer |
| GRTX | Galera Therapeutics, Inc. | Feb 25, 2023 | 1 | $0 | 4 | Feb 28, 2023 | Chief Commercial Officer |
| GRTX | Galera Therapeutics, Inc. | Feb 28, 2022 | 1 | $0 | 4 | Mar 2, 2022 | Chief Commercial Officer |
| GRTX | Galera Therapeutics, Inc. | Oct 8, 2021 | 1 | $0 | 4 | Oct 12, 2021 | Chief Commercial Officer |
| GRTX | Galera Therapeutics, Inc. | Oct 8, 2021 | 0 | $0 | 3 | Oct 12, 2021 | Chief Commercial Officer |